Home > Publications Database > Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study > print

001     154752
005     20240322115503.0
024 7 _ |a pmid:33399945
|2 pmid
024 7 _ |a 10.1007/s00401-020-02255-2
|2 doi
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:97111815
|2 altmetric
024 7 _ |a 33399945
|2 pmid
024 7 _ |a pmc:PMC7847437
|2 pmc
037 _ _ |a DZNE-2021-00342
082 _ _ |a 610
100 1 _ |a Attems, Johannes
|0 0000-0003-1636-1700
|b 0
245 _ _ |a Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study
260 _ _ |a Heidelberg
|c 2021
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1711023726_32505
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Currently, the neuropathological diagnosis of Lewy body disease (LBD) may be stated according to several staging systems, which include the Braak Lewy body stages (Braak), the consensus criteria by McKeith and colleagues (McKeith), the modified McKeith system by Leverenz and colleagues (Leverenz), and the Unified Staging System by Beach and colleagues (Beach). All of these systems use semi-quantitative scoring (4- or 5-tier scales) of Lewy pathology (LP; i.e., Lewy bodies and Lewy neurites) in defined cortical and subcortical areas. While these systems are widely used, some suffer from low inter-rater reliability and/or an inability to unequivocally classify all cases with LP. To address these limitations, we devised a new system, the LP consensus criteria (LPC), which is based on the McKeith system, but applies a dichotomous approach for the scoring of LP (i.e., "absent" vs. "present") and includes amygdala-predominant and olfactory-only stages. α-Synuclein-stained slides from brainstem, limbic system, neocortex, and olfactory bulb from a total of 34 cases with LP provided by the Newcastle Brain Tissue Resource (NBTR) and the University of Pennsylvania brain bank (UPBB) were scanned and assessed by 16 raters, who provided diagnostic categories for each case according to Braak, McKeith, Leverenz, Beach, and LPC systems. In addition, using LP scores available from neuropathological reports of LP cases from UPBB (n = 202) and NBTR (n = 134), JT (UPBB) and JA (NBTR) assigned categories according to all staging systems to these cases. McKeith, Leverenz, and LPC systems reached good (Krippendorff's α ≈ 0.6), while both Braak and Beach systems had lower (Krippendorff's α ≈ 0.4) inter-rater reliability, respectively. Using the LPC system, all cases could be unequivocally classified by the majority of raters, which was also seen for 97.1% when the Beach system was used. However, a considerable proportion of cases could not be classified when using Leverenz (11.8%), McKeith (26.5%), or Braak (29.4%) systems. The category of neocortical LP according to the LPC system was associated with a 5.9 OR (p < 0.0001) of dementia in the 134 NBTR cases and a 3.14 OR (p = 0.0001) in the 202 UPBB cases. We established that the LPC system has good reproducibility and allows classification of all cases into distinct categories. We expect that it will be reliable and useful in routine diagnostic practice and, therefore, suggest that it should be the standard future approach for the basic post-mortem evaluation of LP.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
650 _ 2 |a Autopsy
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Brain Mapping
|2 MeSH
650 _ 2 |a Consensus
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Lewy Bodies: pathology
|2 MeSH
650 _ 2 |a Lewy Body Disease: classification
|2 MeSH
650 _ 2 |a Lewy Body Disease: diagnosis
|2 MeSH
650 _ 2 |a Lewy Body Disease: pathology
|2 MeSH
650 _ 2 |a Observer Variation
|2 MeSH
650 _ 2 |a Reproducibility of Results
|2 MeSH
700 1 _ |a Toledo, Jon B.
|b 1
700 1 _ |a Walker, Lauren
|b 2
700 1 _ |a Gelpi, Ellen
|b 3
700 1 _ |a Gentleman, Steve
|b 4
700 1 _ |a Halliday, Glenda
|b 5
700 1 _ |a Hortobagyi, Tibor
|b 6
700 1 _ |a Jellinger, Kurt
|b 7
700 1 _ |a Kovacs, Gabor G.
|b 8
700 1 _ |a Lee, Edward B.
|b 9
700 1 _ |a Love, Seth
|b 10
700 1 _ |a McAleese, Kirsty E.
|b 11
700 1 _ |a Nelson, Peter T.
|b 12
700 1 _ |a Neumann, Manuela
|0 P:(DE-2719)2810592
|b 13
700 1 _ |a Parkkinen, Laura
|b 14
700 1 _ |a Polvikoski, Tuomo
|b 15
700 1 _ |a Sikorska, Beata
|b 16
700 1 _ |a Smith, Colin
|b 17
700 1 _ |a Grinberg, Lea Tenenholz
|b 18
700 1 _ |a Thal, Dietmar R.
|b 19
700 1 _ |a Trojanowski, John Q.
|0 P:(DE-HGF)0
|b 20
700 1 _ |a McKeith, Ian G.
|b 21
773 _ _ |a 10.1007/s00401-020-02255-2
|g Vol. 141, no. 2, p. 159 - 172
|0 PERI:(DE-600)1458410-4
|n 2
|p 159 - 172
|t Acta neuropathologica
|v 141
|y 2021
|x 1432-0533
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/154752/files/DZNE-2021-00342.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/154752/files/DZNE-2021-00342.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:154752
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2810592
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-29
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b ACTA NEUROPATHOL : 2021
|d 2022-11-29
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2021
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-29
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-29
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-29
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
920 _ _ |l yes
920 1 _ |0 I:(DE-2719)1210003
|k AG Neumann
|l Molecular Neuropathology of Neurodegenerative Diseases
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1210003
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21